Circulating Monocytes as a Marker of Response to Adalimumab in Patients with Hidradenitis Suppurativa: A Single Institution, Real-World Cohort Study

This study examined whether circulating monocytes can predict the response to adalimumab in 143 patients with hidradenitis suppurativa (HS). It found that patients with baseline monocyte counts ≥925/μl had a significantly higher risk of adalimumab ineffectiveness, with a hazard ratio of 5.87. Drug survival rates at 12 and 24 months were higher in patients with lower monocyte counts. The study suggests that monocyte count could serve as a useful biomarker for predicting adalimumab efficacy, as it is easily accessible. Age, BMI, and HS severity did not significantly affect treatment outcomes. Further prospective studies are needed to validate these findings.